Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Feb 16, 2006
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
* The study aims to assess the efficacy and tolerability of risperidone added to lithium, valproate or lamotrigine, or any combination of the three, in patients experiencing a manic episode with depressive or irritable symptoms.
* To assess the back ground and baseline features associated with response/non-response to risperidone plus mood stabilizer in patients with mania with depressive or irritable features.
* To assess the symptomatic dimensions of response of risperidone added to mood stabilizers in patients with mania with depressive or irritable features.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • DSM IV diagnosis of bipolar disorder, currently manic, or mixed manic
- • YMRS score\>/= 16
- * One or more of following:
- • 1. 3 MADRS depression items scoring \>/=3
- • 2. 3 BISS depression items scoring \>/=3
- • 3. YMRS irritability and aggressive items sum score\>/=4
- • Taking lithium, valproate or lamotrigine at stable dose for 4 wks or longer, with adequate serum level
- • age 18 and over
- • Male or female
- • Inpatient or outpatient
- Exclusion Criteria:
- • -
About The University Of Texas Health Science Center At San Antonio
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is a leading academic medical institution dedicated to advancing health through education, research, and patient care. As a prominent sponsor of clinical trials, UT Health San Antonio focuses on innovative medical research aimed at improving health outcomes across diverse populations. With a commitment to excellence, the institution fosters collaboration among its multidisciplinary teams to explore cutting-edge therapies and interventions. Through rigorous scientific inquiry and ethical practices, UT Health San Antonio strives to make meaningful contributions to the field of medicine and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Patients applied
Trial Officials
Vivek Singh, MD
Study Director
UT-SanAntonio
Charles Bowden, MD
Principal Investigator
UT San Antonio
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials